S&P 500   4,574.79
DOW   35,756.88
QQQ   379.12
S&P 500   4,574.79
DOW   35,756.88
QQQ   379.12
S&P 500   4,574.79
DOW   35,756.88
QQQ   379.12
S&P 500   4,574.79
DOW   35,756.88
QQQ   379.12

Translate Bio Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
0.00 (0.00 %)
(As of 09/14/2021)
Today's Range
50-Day Range
52-Week Range
Volume34,832 shs
Average Volume1.66 million shs
Market Capitalization$2.82 billion
P/E Ratio66.71
Dividend YieldN/A

Receive TBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for Translate Bio and its competitors with MarketBeat's FREE daily newsletter.

Translate Bio logo

About Translate Bio

Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. Its products include ICP, HemeScreen, and IV-Cell, and services include primary diagnostic, SmartPath, SmartGen, HemeScreen Panel, and ICE COLD-PCR. The company was founded on March 6, 1997 and is headquartered in New Haven, CT.


See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$138.81 million
Book Value
$4.80 per share


Net Income
$-53.79 million




Market Cap
$2.82 billion
Next Earnings Date
11/4/2021 (Estimated)
Not Optionable


Overall MarketRank

1.41 out of 5 stars

Medical Sector

1081st out of 1,363 stocks

Biological Products, Except Diagnostic Industry

163rd out of 196 stocks

Analyst Opinion: 1.1Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -

Translate Bio (NASDAQ:TBIO) Frequently Asked Questions

Is Translate Bio a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Translate Bio in the last twelve months. There are currently 7 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Translate Bio stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TBIO, but not buy additional shares or sell existing shares.
View analyst ratings for Translate Bio
or view top-rated stocks.

What stocks does MarketBeat like better than Translate Bio?

Wall Street analysts have given Translate Bio a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Translate Bio wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Translate Bio's next earnings date?

Translate Bio is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Translate Bio

How were Translate Bio's earnings last quarter?

Translate Bio, Inc. (NASDAQ:TBIO) issued its earnings results on Wednesday, August, 4th. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.44. The firm had revenue of $72.65 million for the quarter, compared to analyst estimates of $38.23 million. Translate Bio had a trailing twelve-month return on equity of 1.50% and a net margin of 17.97%.
View Translate Bio's earnings history

What price target have analysts set for TBIO?

8 analysts have issued 12 month price objectives for Translate Bio's stock. Their forecasts range from $20.00 to $38.00. On average, they expect Translate Bio's share price to reach $27.50 in the next twelve months. This suggests that the stock has a possible downside of 26.4%.
View analysts' price targets for Translate Bio
or view top-rated stocks among Wall Street analysts.

Who are Translate Bio's key executives?

Translate Bio's management team includes the following people:
  • Ilan Danieli, Chief Executive Officer & Director
  • Ahmed Zaki Sabet, Chief Operating Officer
  • Carl R. Iberger, Chief Financial Officer
  • Ayman A. Mohamed, Vice President-Research & Development
  • Ori Karev, Chief Strategy Officer

What is Craig J. Tuttle's approval rating as Translate Bio's CEO?

13 employees have rated Translate Bio CEO Craig J. Tuttle on Glassdoor.com. Craig J. Tuttle has an approval rating of 5% among Translate Bio's employees. This puts Craig J. Tuttle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Translate Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Translate Bio investors own include Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Novavax (NVAX), Pfizer (PFE), Moderna (MRNA), Johnson & Johnson (JNJ), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and VBI Vaccines (vbiv).

When did Translate Bio IPO?

(TBIO) raised $100 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 7,700,000 shares at $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI acted as the underwriters for the IPO.

What is Translate Bio's stock symbol?

Translate Bio trades on the NASDAQ under the ticker symbol "TBIO."

What is Translate Bio's stock price today?

One share of TBIO stock can currently be purchased for approximately $37.36.

How much money does Translate Bio make?

Translate Bio has a market capitalization of $2.82 billion and generates $138.81 million in revenue each year. The company earns $-53.79 million in net income (profit) each year or ($0.80) on an earnings per share basis.

How many employees does Translate Bio have?

Translate Bio employs 122 workers across the globe.

What is Translate Bio's official website?

The official website for Translate Bio is www.translate.bio.

Where are Translate Bio's headquarters?

Translate Bio is headquartered at 29 HARTWELL AVENUE, LEXINGTON MA, 02421.

How can I contact Translate Bio?

Translate Bio's mailing address is 29 HARTWELL AVENUE, LEXINGTON MA, 02421. The company can be reached via phone at (203) 787-7888.

This page was last updated on 10/27/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.